Sanofi, CytoReason expand AI deal into IBD
CytoReason expands deal with Sanofi to look at IBD
Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated)
Sanofi taps CytoReason’s AI models to target bowel disease
CytoReason Licenses IBD Disease Model to Sanofi in Expanded Alliance
Sanofi, CytoReason expanding collaboration to AI for inflammatory bowel disease targets
CytoReason and Sanofi take collaboration into IBD
Sanofi inks deal to expand AI use for drug discovery
Sanofi extends deal with CytoReason
Sanofi Extends Deal with CytoReason to License IBD Disease Modeling
